RecruitingPhase 2NCT06261021
Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus
Studying Discoid lupus erythematosus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Innovaderm Research Inc.
- Principal Investigator
- Robert Bissonnette, MD, MDInnovaderm Research Inc.
- Intervention
- Ruxolitinib 1.5% cream(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2026
Study locations (2)
- INNO-6051 Site 03, Fredericton, New Brunswick, Canada
- Innovaderm Research Inc., Montreal, Quebec, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06261021 on ClinicalTrials.gov